Feb 27, 2026 10:10 am EST Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
Feb 25, 2026 6:59 am EST Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Feb 2, 2026 8:00 am EST Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
Jan 27, 2026 7:00 am EST Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
Dec 9, 2025 7:00 am EST Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease